Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
Kristin G. Anderson, Ingunn M. Stromnes, Philip D. Greenberg
Cancer Cell (2017) Vol. 31, Iss. 3, pp. 311-325
Open Access | Times Cited: 599

Showing 1-25 of 599 citing articles:

Cancer immunoediting and resistance to T cell-based immunotherapy
Jake S. O’Donnell, Michele W.L. Teng, Mark J. Smyth
Nature Reviews Clinical Oncology (2018) Vol. 16, Iss. 3, pp. 151-167
Closed Access | Times Cited: 1423
Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment
Elisa Peranzoni, Jean Lemoine, Lene Vimeux, et al.
Proceedings of the National Academy of Sciences (2018) Vol. 115, Iss. 17
Open Access | Times Cited: 735
Senolytic CAR T cells reverse senescence-associated pathologies
Corina Amor, Judith Feucht, Josef Leibold, et al.
Nature (2020) Vol. 583, Iss. 7814, pp. 127-132
Open Access | Times Cited: 734
CD8+ T cell differentiation and dysfunction in cancer
Mary Philip, Andrea Schietinger
Nature reviews. Immunology (2021) Vol. 22, Iss. 4, pp. 209-223
Open Access | Times Cited: 666
Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma
David Clark, Saravana M. Dhanasekaran, Francesca Petralia, et al.
Cell (2019) Vol. 179, Iss. 4, pp. 964-983.e31
Open Access | Times Cited: 570
Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
Russell W. Jenkins, Amir Reza Aref, Patrick H. Lizotte, et al.
Cancer Discovery (2017) Vol. 8, Iss. 2, pp. 196-215
Open Access | Times Cited: 466
Challenges and Opportunities for Pancreatic Cancer Immunotherapy
Adham S. Bear, Robert H. Vonderheide, Mark H. O’Hara
Cancer Cell (2020) Vol. 38, Iss. 6, pp. 788-802
Open Access | Times Cited: 439
Fates of CD8+ T cells in Tumor Microenvironment
Nomathamsanqa Resegofetse Maimela, Shasha Liu, Yi Zhang
Computational and Structural Biotechnology Journal (2018) Vol. 17, pp. 1-13
Open Access | Times Cited: 416
Genomic correlates of response to immune checkpoint blockade
Tanya E. Keenan, Kelly P. Burke, Eliezer M. Van Allen
Nature Medicine (2019) Vol. 25, Iss. 3, pp. 389-402
Open Access | Times Cited: 413
Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review)
Masaru Katoh
International Journal of Oncology (2017) Vol. 51, Iss. 5, pp. 1357-1369
Open Access | Times Cited: 391
Current Progress in CAR-T Cell Therapy for Solid Tumors
Shuo Ma, Xinchun Li, Xinyue Wang, et al.
International Journal of Biological Sciences (2019) Vol. 15, Iss. 12, pp. 2548-2560
Open Access | Times Cited: 377
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
Selena Viganó, Dimitrios Alatzoglou, Melita Irving, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 350
IRE1α–XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity
Minkyung Song, Tito A. Sandoval, Chang-Suk Chae, et al.
Nature (2018) Vol. 562, Iss. 7727, pp. 423-428
Open Access | Times Cited: 320
T cell receptor (TCR) signaling in health and disease
Kinjal Shah, Amr Al‐Haidari, Jianmin Sun, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 315
CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Jessica Wagner, Elizabeth Wickman, Christopher DeRenzo, et al.
Molecular Therapy (2020) Vol. 28, Iss. 11, pp. 2320-2339
Open Access | Times Cited: 293
T cell–induced CSF1 promotes melanoma resistance to PD1 blockade
Natalie J. Neubert, Martina Schmittnaegel, Natacha Bordry, et al.
Science Translational Medicine (2018) Vol. 10, Iss. 436
Open Access | Times Cited: 269
Lipid droplet‐dependent fatty acid metabolism controls the immune suppressive phenotype of tumor‐associated macrophages
Hao Wu, Yijie Han, Y Rodríguez Sillke, et al.
EMBO Molecular Medicine (2019) Vol. 11, Iss. 11
Open Access | Times Cited: 260
The Mechanism of Anti–PD-L1 Antibody Efficacy against PD-L1–Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector
Wenjuan Dong, Xiaojin Wu, Shoubao Ma, et al.
Cancer Discovery (2019) Vol. 9, Iss. 10, pp. 1422-1437
Open Access | Times Cited: 251
Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy
Kathrin Renner, Christina Bruß, Annette Schnell, et al.
Cell Reports (2019) Vol. 29, Iss. 1, pp. 135-150.e9
Open Access | Times Cited: 237
Understanding the tumor microenvironment for effective immunotherapy
Habib Sadeghi Rad, James Monkman, Majid Ebrahimi Warkiani, et al.
Medicinal Research Reviews (2020) Vol. 41, Iss. 3, pp. 1474-1498
Open Access | Times Cited: 230
Self‐Amplified Drug Delivery with Light‐Inducible Nanocargoes to Enhance Cancer Immunotherapy
Bing Feng, Bo Hou, Zhiai Xu, et al.
Advanced Materials (2019) Vol. 31, Iss. 40
Closed Access | Times Cited: 228
Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy
Filippo Galli, Jesus Vera Aguilera, Belinda Palermo, et al.
Journal of Experimental & Clinical Cancer Research (2020) Vol. 39, Iss. 1
Open Access | Times Cited: 228
Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus–Driven Production of a Bispecific T-cell Engager
Anna Wing, Carlos Alberto Fajardo, Avery D. Posey, et al.
Cancer Immunology Research (2018) Vol. 6, Iss. 5, pp. 605-616
Open Access | Times Cited: 221
Biomineralized Bacterial Outer Membrane Vesicles Potentiate Safe and Efficient Tumor Microenvironment Reprogramming for Anticancer Therapy
Shuang Qing, Chengliang Lyu, Li Zhu, et al.
Advanced Materials (2020) Vol. 32, Iss. 47
Closed Access | Times Cited: 221
Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment
Alba Nicolás‐Boluda, Javier Vaquero, Lene Vimeux, et al.
eLife (2021) Vol. 10
Open Access | Times Cited: 215
Page 1 - Next Page

Scroll to top